Article
Overlapping features of therapy-related and de novo NPM1-mutated AML.
Blood - 13 Apr 2023
Othman Jad, Meggendorfer Manja, Tiacci Enrico, Thiede Christian, Schlenk Richard, Dillon Richard, Stasik Sebastian, Venanzi Alessandra, Bertoli Sarah, Delabesse Eric, Dumas Pierre-Yves, Pigneux Arnaud, Bidet Audrey, Gilkes Amanda F, Thomas Ian, Voso Maria Teresa, Rambaldi Alessandro, Brunetti Lorenzo, Perriello Vincenzo M, Andresen Vibeke, Gjertsen Bjorn T, Martelli Maria Paola, Récher Christian, Röllig Christoph, Bornhäuser Martin, Serve Hubert, Müller-Tidow Carsten, Baldus Claudia D, Haferlach Tortsten, Russell Nigel, Falini Brunangelo
Abstract excerpt
NPM 1-mutated acute myeloid leukemia (AML) shows unique features. However, the characteristics of "therapy-related" NPM1-mutated AML (t-NPM1 AML) are poorly understood. We compared the genetics, transcriptional profile, and clinical outcomes of t-NPM1 AML, de novo NPM1-mutated AML (dn-NPM1 AML), and therapy-related AML (t-AML) with wild-type NPM1 (t-AML). Normal karyotype was more frequent in t-NPM1 AML (n =...
Topics
Join the communities discussing this publication.